PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.60%
Revenue growth at 50-75% of MRVL's 14.79%. Martin Whitman would worry about competitiveness or product relevance.
11.73%
Gross profit growth at 50-75% of MRVL's 17.21%. Martin Whitman would question if cost structure or brand is lagging.
57.04%
EBIT growth above 1.5x MRVL's 5.90%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
57.04%
Operating income growth above 1.5x MRVL's 5.90%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
50.26%
Net income growth above 1.5x MRVL's 4.77%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
37.50%
EPS growth of 37.50% while MRVL is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
46.67%
Diluted EPS growth above 1.5x MRVL's 7.14%. David Dodd would see if there's a robust moat protecting these shareholder gains.
9.35%
Slight or no buybacks while MRVL is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
1.42%
Slight or no buyback while MRVL is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
168.00%
OCF growth above 1.5x MRVL's 66.88%. David Dodd would confirm a clear edge in underlying cash generation.
185.90%
FCF growth above 1.5x MRVL's 73.11%. David Dodd would verify if the firm’s strategic investments yield superior returns.
298.63%
10Y revenue/share CAGR at 50-75% of MRVL's 399.62%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
152.62%
5Y revenue/share CAGR under 50% of MRVL's 399.62%. Michael Burry would suspect a significant competitive gap or product weakness.
21.74%
3Y revenue/share CAGR under 50% of MRVL's 173.24%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
3335.25%
10Y OCF/share CAGR 1.25-1.5x MRVL's 2771.12%. Bruce Berkowitz would confirm if the firm's long-term capital allocation yields better cash returns.
1162.24%
Below 50% of MRVL's 2771.12%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
63.35%
3Y OCF/share CAGR under 50% of MRVL's 587.48%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
442.52%
Net income/share CAGR above 1.5x MRVL's 119.06% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
174.65%
5Y net income/share CAGR 1.25-1.5x MRVL's 119.06%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
73.45%
Below 50% of MRVL's 439.05%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
845.10%
Positive growth while MRVL is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
212.61%
Positive 5Y equity/share CAGR while MRVL is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
40.83%
3Y equity/share CAGR 1.25-1.5x MRVL's 31.66%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.54%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-10.55%
Inventory is declining while MRVL stands at 40.98%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
6.08%
Asset growth at 50-75% of MRVL's 9.18%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
-1.21%
We have a declining book value while MRVL shows 9.12%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
5.12%
R&D dropping or stable vs. MRVL's 14.23%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-8.02%
We cut SG&A while MRVL invests at 18.10%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.